You don't have to agree with me. In fact, no one has to ever agree with me. But do as I tell you to. Then again, you don't work for me. So you'll do what you want to. But I will tell you that if you do as I tell you either you agree or not, you will most likely see a positive outcome. Then you're the genius and the credit goes to you. If the program fails, then it's my fault. That's how I work.
I have no idea which GPO you belong to and you do know that different GPOs have different pricing. I'll just pick one particular GPO because I have the pricing memorized.
1gram Ceftriaxone vial costs $1.19 and 50ml minibag plus with vial mate costs $1.74 - before rebate. that's $2.73 for 1 gram ceftriaxone with 14 day expiration before mixing. You're paying $7 and change for frozen Rocephin? That's competitive...you must have some sweetheart deal because I usually see $9 to $10 for a bag of frozen ceftriaxone...total rip off.
So... you tell me why you would spend $4+ more per dose of frozen over vial + vial mate? You convince me. My stance is...I wouldn't use frozen unless it's a cheaper alternative like frozen PCN and/or vanco (sometimes).
And don't say labor cost.... it should not take more than 2 hour per day to batch all your antibiotics and convert to vials. I've done enough myself plus converted enough hospitals to know that "labor cost" excuse doesn't fly.
Zosyn 3.375 vials costs $16.01 (new pricing since July)...with a bag attachement, it's $17.75. Frozen Zosyn costs $19.75 to $20+ for the same strength...
You tell me why you'd want to pay $2 per dose more. If you're at an ID fellowship site....assuming you have more than 500 beds..you could be going through 3000 to 4000 doses of zosyn per month. That's a lot extra money.
Again, convince me why using frozen is the way to go instead of vial plus minibag plus with vial mate.
What's my break even poing anecdotally speaking? about 50 cents a dose....more than enough to cover labor. Also, you will most likely see less waste with vial+vial mate with a longer expiration.
while I disagree with you on almost everything, I respect your opinion so help me out if you can. Our integrated service line manager is on me again to be prepared for all scenarios if a generic pip/tazo ever comes out. My question, Baxter maintains a 83% share of the ceftriaxone molecule through it's frozen bag system even though it gets a $4.23 premium vs generic in vials.
What premium hits the break even for pip/tazo? Same range or less given that we are still going to save money even if we stay frozen brand because as the generic vial drops so does the spread vs frozen.
thanks
